EUVIMEDEUVIMED entdecken
Crossref

Pharmacy projects target SGLT2 inhibitors for heart failure

Kate Traynor

American Journal of Health-System Pharmacy · 2023

DOI: 10.1093/ajhp/zxad042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Health-System Pharmacy, 2023. Verfasst von Kate Traynor. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Diabetes Mellitus, Type 2, Pharmacy. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Now that national guidelines recommend sodium-glucose cotransporter-2 (SGLT2) inhibitors for the treatment of heart failure, pharmacists are identifying prescribing gaps and targeting patients who can benefit from the therapy. At NYC Health + Hospitals/Kings County in Brooklyn, NY, just 23 patients who were admitted for heart failure—or for ischemic stroke with type 2 diabetes—received a discharge prescription for an SGLT2 inhibitor in 2021, said Shireen Farzadeh, transitions of care clinical pharmacist at the 639-bed public teaching hospital. Last year, in response to updated heart failure guidelines from the American College of Cardiology (ACC), American Heart Association (AHA), and Heart Failure Society of America (HFSA) and revised diabetes management guidelines from the American Diabetes Association (ADA), the hospital launched a pharmacist-led service to boost discharge prescribing of the SGLT2 inhibitor empagliflozin. The results were dramatic. From April through August 2022, 110 patients who were admitted with heart failure or ischemic stroke with type 2 diabetes were discharged with a supply of empagliflozin or a prescription for it.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsHeart FailureDiabetes Mellitus, Type 2PharmacyHumans

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Zitieren

APA

Traynor, K. (2023). Pharmacy projects target SGLT2 inhibitors for heart failure. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxad042

Vancouver

Traynor K. Pharmacy projects target SGLT2 inhibitors for heart failure. American Journal of Health-System Pharmacy. 2023. doi:10.1093/ajhp/zxad042

BibTeX
@article{Traynor2023,
  author = {Traynor, Kate},
  title = {Pharmacy projects target SGLT2 inhibitors for heart failure},
  journal = {American Journal of Health-System Pharmacy},
  year = {2023},
  doi = {10.1093/ajhp/zxad042}
}
Kostenlos starten →